S
Shinta Mizuno
Researcher at Keio University
Publications - 66
Citations - 1925
Shinta Mizuno is an academic researcher from Keio University. The author has contributed to research in topics: Inflammatory bowel disease & Ulcerative colitis. The author has an hindex of 20, co-authored 65 publications receiving 1338 citations.
Papers
More filters
Journal ArticleDOI
Mammalian target of rapamycin and glycogen synthase kinase 3 differentially regulate lipopolysaccharide-induced interleukin-12 production in dendritic cells
Masashi Ohtani,Shigenori Nagai,Shuhei Kondo,Shinta Mizuno,Kozue Nakamura,Masanobu Tanabe,Tsutomu Takeuchi,Satoshi Matsuda,Shigeo Koyasu +8 more
TL;DR: It is suggested that mTOR and GSK3 pathways regulate the Th1/Th2 balance though the regulation of IL-12 expression in DCs, and the signaling pathway downstream of PI3K would be a good target to modulate the Th2 balance in immune responses in vivo.
Journal ArticleDOI
Bifidobacterium-Rich Fecal Donor May Be a Positive Predictor for Successful Fecal Microbiota Transplantation in Patients with Irritable Bowel Syndrome.
Shinta Mizuno,Tatsuhiro Masaoka,Makoto Naganuma,Taishiro Kishimoto,Momoko Kitazawa,Shunya Kurokawa,Moeko Nakashima,Kozue Takeshita,Wataru Suda,Wataru Suda,Masaru Mimura,Masahira Hattori,Masahira Hattori,Takanori Kanai +13 more
TL;DR: FMT for patients with IBS is safe, and relatively effective, and Bifidobacterium-rich fecal donor may be a positive predictor for successful FMT, which showed that FMT improved stool form and psychological status of IBS patients.
Journal ArticleDOI
The effect of fecal microbiota transplantation on psychiatric symptoms among patients with irritable bowel syndrome, functional diarrhea and functional constipation: An open-label observational study.
Shunya Kurokawa,Taishiro Kishimoto,Shinta Mizuno,Tatsuhiro Masaoka,Makoto Naganuma,Kuo Ching Liang,Momoko Kitazawa,Moeko Nakashima,Chie Shindo,Wataru Suda,Masahira Hattori,Takanori Kanai,Masaru Mimura +12 more
TL;DR: The results suggest that depression and anxiety symptoms may be improved by FMT regardless of gastrointestinal symptom change in patients with IBS, FDr and FC, and the increase of microbiota diversity may help to improve patient's mood.
Journal ArticleDOI
Efficacy of Indigo Naturalis in a Multicenter Randomized Controlled Trial of Patients With Ulcerative Colitis.
Makoto Naganuma,Shinya Sugimoto,Keiichi Mitsuyama,Taku Kobayashi,Naoki Yoshimura,Hidehisa Ohi,Shinji Tanaka,Akira Andoh,Naoki Ohmiya,Keiichiro Saigusa,Takayuki Yamamoto,Yuichi Morohoshi,Hitoshi Ichikawa,Katsuyoshi Matsuoka,Tadakazu Hisamatsu,Kenji Watanabe,Shinta Mizuno,Wataru Suda,Masahira Hattori,Shinji Fukuda,Akiyoshi Hirayama,Takayuki Abe,Mamoru Watanabe,Toshifumi Hibi,Yasuo Suzuki,Takanori Kanai +25 more
TL;DR: In a randomized, placebo-controlled trial, 8 weeks of Indigo naturalis (0.5-2.0 g per day) is found to be effective in inducing a clinical response in patients with UC, but IN should not yet be used because of the potential for adverse effects, including pulmonary arterial hypertension.
Journal ArticleDOI
A Single Species of Clostridium Subcluster XIVa Decreased in Ulcerative Colitis Patients.
Kozue Takeshita,Shinta Mizuno,Yohei Mikami,Tomohisa Sujino,Keiichiro Saigusa,Katsuyoshi Matsuoka,Makoto Naganuma,Tadashi Sato,Toshihiko Takada,Hirokazu Tsuji,Akira Kushiro,Koji Nomoto,Takanori Kanai +12 more
TL;DR: Findings suggest that the recovery of homeostasis in the intestinal microbiota could cure inflammatory bowel disease through translational research by analysis of ulcerative colitis patients' intestinal microbiota and clarify the effects of them on inflammation.